Lilly Asia Ventures

With roughly $4.5B under management, Lilly Asia Ventures ranks among the active investors in the AI space. That capital is deployed across their portfolio of AI-focused bets.

Across their portfolio, Lilly Asia Ventures has consistently backed companies in AI, Health, Biotech, Asia. These focus areas reflect where the firm sees the strongest risk-adjusted returns in AI.

Awaira currently tracks 1 companies in Lilly Asia Ventures's portfolio. The actual number may be higher, as some early-stage investments are not publicly disclosed.

The firm's sweet spot is Multi-stage investing. That said, strong conviction deals can pull them into earlier or later rounds depending on the company.

The most notable deal on record for Lilly Asia Ventures is Lilly Asia Ventures is a multi-stage venture capital firm founded in 2008, headquartered in China, managing approximately $4.5B in assets under management. The firm concentrates on AI, Health, Biotech, Asia, deploying capital primarily at the multi-stage level. Notable AI portfolio companies include Insilico Medicine. Lilly Asia Ventures has participated in 1 funding round tracked by Awaira, deploying capital across AI, Health, Biotech sectors. The firm's investment strategy emphasizes AI applications in healthcare and life sciences. Awaira assigns Lilly Asia Ventures an investor score of 60/100 based on portfolio strength, AI sector exposure, and market activity. The firm investment thesis centers on identifying AI companies that demonstrate strong technical moats, clear paths to revenue, and potential for category leadership within their respective segments. Lilly Asia Ventures evaluates opportunities based on team quality, market timing, technology differentiation, and capital efficiency. Portfolio companies including Insilico Medicine reflect the firm emphasis on backing founders who combine deep technical expertise with commercial execution capability.. It is the kind of investment that defines a fund's reputation in the AI ecosystem.